Felix Middle East Direct Sales Strategy
Filed with ASX · · 3 pages · English
Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is accelerating the commercialisation of its Felix™ sperm-selection device through a direct sales engagement strategy in key Middle East markets, focused on converting clinical interest into purchasing behaviour, account activation, and recurring cartridge revenue. The company’s direct-sales strategy, providing greater control over execut
Story so far
Earlier from Memphasys
- Completion of Entitlement Offer
- MEM Secures Indian Supply Deal Under Go-Direct Strategy
- Memphasys Expands Felix Commercial Footprint in Japan
- Response to ASX Aware Letter
- Non-Renounceable Issue
Later from Memphasys
- Memphasys Implements Leadership Restructure
- Key MENA Partner Secures Early Felix Cartridge Order
- Memphasys Secures Long-Term European Supply Agreement
- Memphasys Secures CE Mark Approval for Felix System
- Placement of Shortfall Securities from the Entitlement Offer
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys